Biofrontera (BFRI) Cash from Financing Activities (2020 - 2025)
Biofrontera has reported Cash from Financing Activities over the past 6 years, most recently at $2.4 million for Q4 2025.
- For Q4 2025, Cash from Financing Activities fell 41.98% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $6.1 million, down 58.87%, while the annual FY2025 figure was $10.8 million, 26.86% down from the prior year.
- Cash from Financing Activities for Q4 2025 was $2.4 million at Biofrontera, down from $4.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $43.8 million in Q4 2021 and troughed at -$298000.0 in Q3 2024.
- A 5-year average of $7.3 million and a median of $4.3 million in 2022 define the central range for Cash from Financing Activities.
- Biggest five-year swings in Cash from Financing Activities: skyrocketed 3926.45% in 2022 and later plummeted 150.42% in 2024.
- Year by year, Cash from Financing Activities stood at $43.8 million in 2021, then crashed by 89.44% to $4.6 million in 2022, then skyrocketed by 45.01% to $6.7 million in 2023, then plummeted by 39.68% to $4.0 million in 2024, then plummeted by 41.98% to $2.4 million in 2025.
- Business Quant data shows Cash from Financing Activities for BFRI at $2.4 million in Q4 2025, $4.0 million in Q4 2024, and -$298000.0 in Q3 2024.